Iatrogenic Cushing's syndrome has been described following concomitant administration of P450 inhibitors and inhaled budesonide in patients with HIV or cystic fibrosis, 8, 9 but the clinical significance of this drug interaction after hematopoietic SCT remains unknown.
The development of iatrogenic Cushing's syndrome in one of our alloHCT patient who received BUD as the sole source of steroids, which led us to explore the frequency of Cushing's syndrome, or other manifestations of significant systemic exposure to exogenous steroids in patients who had received alloHCT and were receiving both BUD and an azole drug.
Following approval from Institutional Review Board, we reviewed the medical charts of the 60 patients who received an alloHCT between January 2008 and August 2011. Five patients met the study criteria of a diagnosis of acute or chronic GvHD with cessation of systemic steroids while continuing BUD for a further 21 days or more. The charts were reviewed for evidence of clinical development of iatrogenic Cushing's syndrome and for abnormalities in morning plasma cortisol levels. Patient details are summarized in Table 1 .
BUD was initiated at 9 mg per day and the dose was titrated according to standard GvHD response criteria. All patients were receiving either fluconazole (n ¼ 3) or voriconazole (n ¼ 2) for fungal prophylaxis. Although no subject had received systemic steroids for at least 21 days, in all patients, BUD administration alone was associated with suppression of morning plasma cortisol, indicating systemic absorption and significant plasma levels of the 'non-absorbed' steroid. All these patients also had rapid (within 3 weeks) onset of iatrogenic Cushing's syndrome (new onset ¼ 4, worsening ¼ 1), with median weight gain of 5.7 kg (range ¼ 4.0 --7.1 kg). All patients developed facial mooning, central obesity and glucose intolerance. Plasma cortisol remained suppressed at 1 mg/ dL even when BUD was reduced to 3 mg per day, at which dose we observed exacerbation of gut and/or skin GvHD, requiring dose re-escalation. In one patient (patient number 2), in whom BUD was stopped for 2 weeks, morning plasma cortisol rose to 11 mg/dL; resumption of BUD again suppressed morning plasma cortisol to 1 mg/dL.
Oral BUD has high ratio of topical-to-systemic activity and substantial first-pass elimination (80 --90%) that should limit systemic effects. Following oral administration of 9 mg BUD in healthy subjects, a peak plasma concentration of 5 nmol/L is observed, and the area under the plasma concentration time curve is approximately 30 nmol/h/L. In patients with GI GvHD, however, systemic entry through an inflamed gut wall may lead to substantially different absorption and pharmacokinetics. Certainly, the systemic bioavailability of budenoside is higher in patients with Crohn's disease compared with healthy subjects (21% vs 9%), so that 9 mg of oral BUD is equivalent to 40 mg of oral prednisone. 10 In alloHCT patients, systemic concentrations of the drug may be further increased by concomitant azole administration.
Hence, the combination of gut GVHD and concomitant azole administration serves to increase systemic availability of BUD to levels that consistently induce Cushing's syndrome, offsetting the nominal advantages of the drug over systemic steroids. If confirmed, these results will suggest limited systemic benefit from substituting BUD for prednisone in patients with gut GvHD who are receiving azole drugs. 
